Published in Medical Letter on the CDC and FDA, November 12th, 2006
If approved by the Food and Drug Administration (FDA), lofexidine would be the first non-addictive, non-narcotic treatment for relieving the withdrawal symptoms associated with opiate detoxification approved in the United States.
Investigators are currently recruiting 264 patients to participate in the in-patient, randomized, double-blind trial that will be conducted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.